These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1642467)

  • 1. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Wallace DC; Shoffner JM; Watts RL; Juncos JL; Torroni A
    Ann Neurol; 1992 Jul; 32(1):113-4. PubMed ID: 1642467
    [No Abstract]   [Full Text] [Related]  

  • 2. Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson's disease.
    Ebadi M; Muralikrishnan D; Pellett LJ; Murphy T; Drees K
    Proc West Pharmacol Soc; 2000; 43():55-63. PubMed ID: 11056957
    [No Abstract]   [Full Text] [Related]  

  • 3. Mitochondrial oxidative phosphorylation defects in Parkinson's disease.
    Shoffner JM; Watts RL; Juncos JL; Torroni A; Wallace DC
    Ann Neurol; 1991 Sep; 30(3):332-9. PubMed ID: 1952821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Idiopathic Parkinson disease and mitochondrial functions].
    Tranchant C; Weess C; Warter JM
    Rev Neurol (Paris); 1995 Mar; 151(3):157-60. PubMed ID: 7676150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Dexter DT; Sian J; Rose S; Hindmarsh JG; Mann VM; Cooper JM; Wells FR; Daniel SE; Lees AJ; Schapira AH
    Ann Neurol; 1994 Jan; 35(1):38-44. PubMed ID: 8285590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxiredoxin 5 links mitochondrial redox signalling with calcium dynamics: impact on Parkinson's disease.
    Davey GP; Bolaños JP
    J Neurochem; 2013 May; 125(3):332-3. PubMed ID: 23442153
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative disease.
    Ogawa O; Zhu X; Perry G; Smith MA
    Sci Aging Knowledge Environ; 2002 Oct; 2002(41):pe16. PubMed ID: 14603007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities of the electron transport chain in idiopathic Parkinson's disease.
    Parker WD; Boyson SJ; Parks JK
    Ann Neurol; 1989 Dec; 26(6):719-23. PubMed ID: 2557792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?
    Michel PP; Ruberg M; Hirsch E
    Sci STKE; 2006 Apr; 2006(332):pe19. PubMed ID: 16639033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metallothionein and oxidation reactions in Parkinson's disease.
    Ebadi M; Pfeiffer RF; Murrin LC; Shiraga H
    Proc West Pharmacol Soc; 1991; 34():285-90. PubMed ID: 1788299
    [No Abstract]   [Full Text] [Related]  

  • 11. [Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
    Mizuno Y
    Rinsho Shinkeigaku; 1989 Dec; 29(12):1494-6. PubMed ID: 2698296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detrimental deletions: mitochondria, aging and Parkinson's disease.
    Biskup S; Moore DJ
    Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty diet, mitochondria and Parkinson's disease.
    Peers R
    N Z Med J; 1997 Apr; 110(1041):132. PubMed ID: 9140421
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease.
    Chinta SJ; Andersen JK
    Free Radic Biol Med; 2006 Nov; 41(9):1442-8. PubMed ID: 17023271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson's disease.
    Soto-Otero R; Sanmartín-Suárez C; Sánchez-Iglesias S; Hermida-Ameijeiras A; Sánchez-Sellero I; Méndez-Alvarez E
    J Biochem Mol Toxicol; 2006; 20(5):209-20. PubMed ID: 17009235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: relevance to Parkinson's disease.
    Arduíno DM; Esteves AR; Cardoso SM; Oliveira CR
    Neurochem Int; 2009 Sep; 55(5):341-8. PubMed ID: 19375464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects.
    Ferrer I
    Prog Neurobiol; 2009 Jun; 88(2):89-103. PubMed ID: 19482226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease.
    Hanagasi HA; Ayribas D; Baysal K; Emre M
    Int J Neurosci; 2005 Apr; 115(4):479-93. PubMed ID: 15809215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel imine antioxidants at low nanomolar concentrations protect dopaminergic cells from oxidative neurotoxicity.
    Hajieva P; Mocko JB; Moosmann B; Behl C
    J Neurochem; 2009 Jul; 110(1):118-32. PubMed ID: 19486265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.